B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund Cuts Holdings in Gilead Sciences, Inc. (GILD)

B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.5% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 40,806 shares of the biopharmaceutical company’s stock after selling 3,314 shares during the period. B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund’s holdings in Gilead Sciences were worth $2,772,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GILD. Parnassus Investments CA lifted its stake in Gilead Sciences by 37.4% in the 1st quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock valued at $1,110,228,000 after acquiring an additional 4,556,901 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Gilead Sciences by 9.8% in the 1st quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock valued at $2,076,368,000 after acquiring an additional 2,727,063 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. lifted its stake in Gilead Sciences by 75.0% in the 1st quarter. Los Angeles Capital Management & Equity Research Inc. now owns 2,549,292 shares of the biopharmaceutical company’s stock valued at $173,148,000 after acquiring an additional 1,092,206 shares in the last quarter. AQR Capital Management LLC lifted its stake in Gilead Sciences by 25.7% in the 1st quarter. AQR Capital Management LLC now owns 5,213,046 shares of the biopharmaceutical company’s stock valued at $354,070,000 after acquiring an additional 1,066,172 shares in the last quarter. Finally, Swiss National Bank lifted its stake in Gilead Sciences by 26.9% in the 1st quarter. Swiss National Bank now owns 4,668,124 shares of the biopharmaceutical company’s stock valued at $317,059,000 after acquiring an additional 989,400 shares in the last quarter. Hedge funds and other institutional investors own 74.05% of the company’s stock.

Several equities research analysts have commented on the company. TheStreet upgraded Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Zacks Investment Research cut Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Monday. ValuEngine upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 7th. Berenberg Bank restated a “buy” rating and issued a $96.00 target price (up previously from $86.00) on shares of Gilead Sciences in a research note on Wednesday, September 6th. Finally, Vetr upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 target price on the stock in a research note on Wednesday, September 6th. Eleven analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $83.06.

COPYRIGHT VIOLATION NOTICE: “B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund Cuts Holdings in Gilead Sciences, Inc. (GILD)” was first reported by Stock Observer and is the sole property of of Stock Observer. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.thestockobserver.com/2017/09/12/b-s-pension-fund-trustee-ltd-acting-for-the-british-steel-pension-fund-cuts-holdings-in-gilead-sciences-inc-gild.html.

In other news, CFO Robin L. Washington sold 51,820 shares of the business’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $85.00, for a total value of $4,404,700.00. Following the completion of the sale, the chief financial officer now owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the sale, the insider now directly owns 3,199,969 shares of the company’s stock, valued at approximately $227,197,799. The disclosure for this sale can be found here. In the last three months, insiders sold 466,819 shares of company stock valued at $36,740,240. 1.30% of the stock is currently owned by corporate insiders.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) traded down 0.58% during trading on Tuesday, reaching $84.03. The company’s stock had a trading volume of 4,531,233 shares. The stock’s 50-day moving average is $75.90 and its 200-day moving average is $69.72. The stock has a market cap of $109.74 billion, a P/E ratio of 9.13 and a beta of 1.19. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $86.27.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. During the same quarter in the previous year, the company posted $3.08 earnings per share. The company’s revenue was down 8.2% compared to the same quarter last year. Equities research analysts anticipate that Gilead Sciences, Inc. will post $8.75 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.46%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply